United States · Platforms & data · MarketBeat
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch

Detailed summary
Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for Alzheimer’s disease agitation. Speaking at the UBS Biopharma Conference in London, Chief Financial Off
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)




